Dulaglutide vs Retatrutide
Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Dulaglutide
1.5–1.5 mg
Retatrutide
4–8 mg
Frequency
Dulaglutide
Once weekly
Retatrutide
Once weekly
Administration
Dulaglutide
Subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle length
Dulaglutide
Ongoing/indefinite
Retatrutide
12+ weeks
Onset speed
Dulaglutide
Gradual (3-4 weeks)
Retatrutide
Moderate (1-2 weeks)
Evidence level
Dulaglutide
Strong human trials (Phase 3 or FDA approved)
Retatrutide
Moderate human trials (Phase 1-2)
Benefit ratings
Metabolic
Weight Management
Healing & Recovery
Weight Loss Power
Metabolic Health
Appetite Control
Compound specifications
Dulaglutide
Molecular formula
C2646H4044N704O836S18 (complete fusion protein homodimer)
Molecular weight
~63 kDa (~59,670 Da per chain)
Half-life
~5 days (terminal elimination); Tmax ~48 hours; steady state in 2–4 weeks; accumulation ratio 1.56 at 1.5 mg
Bioavailability
47–65% after subcutaneous injection (dose-dependent); apparent clearance 0.142 L/h
CAS number
923950-08-7
Retatrutide
Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2
Dosing compared
Dulaglutide
Subcutaneous
4 weeks before increasing
0.75 mg
Once weekly · 4 weeks before increasing
FDA-approved starting dose for type 2 diabetes. Injected under the skin of the abdomen, thigh, or upper arm on the same day each week [4].
Ongoing
1.5 mg
Once weekly · Ongoing
Common maintenance dose. The dose can be raised from 0.75 mg after at least 4 weeks if more blood-sugar control is needed [1][4].
Ongoing
3.0–4.5 mg
Once weekly · Ongoing
FDA-approved higher doses. In the AWARD-11 trial, stepping up to 3.0 mg then 4.5 mg gave added blood-sugar and weight benefits; 4.5 mg is the maximum dose [1].
Retatrutide
Subcutaneous
Weeks 1-4
2 mg
Once weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)
Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
Maintenance after titration
4-8 mg
Once weekly · Maintenance after titration
Mid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
Maintenance (highest studied)
12 mg
Once weekly · Maintenance (highest studied)
Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Best suited for
Dulaglutide
Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Side effects
Dulaglutide
Common
- Nausea
- Diarrhea and abdominal pain
- Vomiting
- Decreased appetite
Uncommon
- Injection site reactions and fatigue
Serious
- Acute pancreatitis
- Gallbladder disease
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Safety & evidence
Dulaglutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models. This risk is contraindicated in patients with personal or family history of MTC [6] or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common. Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor data [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
- Known serious hypersensitivity to dulaglutide or any excipient [6]
- Type 1 diabetes mellitus or diabetic ketoacidosis (not indicated) [6]
Retatrutide
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Which is right for you?
Choose Dulaglutide if...
- Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
- Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
- Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
- Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization